NIH
-
Long COVID affects millions of children. The largest pediatric trial so far launches this year.
One NIH study will test low-dose naltrexone, while other upcoming trials will test larozitide and taurine.
-
New RECOVER-TLC trials won’t enroll until summer. Nearly two years after the program’s launch.
The RECOVER-Treating Long COVID initiative is set to begin enrolling participants in new clinical trials this summer, which will mark nearly two years after the National of Institutes of Health (NIH) effort launched with promises to deliver greater urgency for this chronic disease impacting tens of millions of Americans.
-
HHS hosts event and announces new initiatives for Lyme disease, but advocates are skeptical about follow-through
The Lyme disease roundtable followed a similar event on Long COVID, which still hasn’t led to action on the disease
-
It’s been a month. And we still don’t know much about Kennedy’s Long COVID consortium.
Preliminary meetings are occurring amid the ongoing government shutdown, while some advocates call for Health Secretary Kennedy’s removal
-
Vyvgart brought us back to life, but the Long COVID trial was canceled. We are calling on the NIH and HHS to study the drug.
We are a group of 53 individuals with Long COVID from across the U.S. In 2023, we joined a Long COVID clinical trial for Vyvgart (efgartigimod), a drug approved by the Food and Drug Administration (FDA) for the autoimmune disease myasthenia gravis. Without warning, the trial was canceled in June 2024.
-
Kennedy’s HHS commits to Long COVID, but without clear funding
Following two roundtable discussions with leading researchers and government officials — but limited patient engagement — HHS announced a public awareness campaign and medical resource platform
-
RECOVER-TLC announces new Long COVID clinical trials, receives mixed reactions from patient community
Some Long COVID advocates and researchers, including those who advised the National Institutes of Health’s initiative, say RECOVER-TLC isn’t living up to its promised ambition.
-
Secretary Kennedy promises to support Long COVID treatment research in Senate hearing, says son is “dramatically affected”
Long COVID was at the top of legislators’ priority list during today’s Senate Health, Education, Labor, and Pensions (HELP) Committee hearing with Health Secretary Robert F. Kennedy Jr. Senator Bill Cassidy (R-L.A.), who chairs the HELP Committee, asked about federal health agencies’ commitment to addressing Long COVID in his first question to the Secretary.
-
UPDATE: RECOVER Long COVID pathobiology grants restored
Long COVID research grants from the National Institutes of Health’s RECOVER program will be restored following news stories about their abrupt cancellations and advocacy to restore the funding, according to patient representatives in the initiative.
-
RECOVER grants for Long COVID pathobiology research are among those cut under new NIH directive
Some grants for Long COVID pathobiology research in the National Institutes of Health’s RECOVER program are among those rescinded by the federal government this week under a new order to cut all funding for COVID-related research. Up to 45 grants awarded in 2022 and 2023 may have been revoked, as well as more recent grants…
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
-
A new aid in the doctor’s office: Introducing the Long COVID Treatment Guide
-
Where have all the Long COVID clinics gone?
-
National COVID-19 trends, March 10
-
Research updates, March 10
-
My child and I both have Long COVID. Even in COVID-aware spaces, we are excluded because of their pre-existing disability.
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance